切换至 "中华医学电子期刊资源库"

第五届中国出版政府奖音像电子网络出版物奖提名奖

中国科技核心期刊

中国科学引文数据库(CSCD)来源期刊

中华重症医学电子杂志 ›› 2018, Vol. 04 ›› Issue (02) : 141 -146. doi: 10.3877/cma.j.issn.2096-1537.2018.02.008

所属专题: 文献

重症感染与免疫

氢化可的松在肺部感染致感染性休克中应用的前瞻性临床研究
吕清泉1, 顾小花1, 陈齐红1, 吕应鸣2, 郑瑞强1,()   
  1. 1. 225000 江苏扬州,江苏省苏北人民医院重症医学科
    2. 225700 江苏兴化,兴化市德美康复医院普外科
  • 收稿日期:2018-03-11 出版日期:2018-05-28
  • 通信作者: 郑瑞强
  • 基金资助:
    国家自然科学基金资助项目(81670065); 江苏省社会发展重点专项(BE2017691)

Initiation of hydrocortisone treatment for pneumonia induced septic shock: a prospective clinical study

Qingquan Lyu1, Xiaohua Gu1, Qihong Chen1, Yingming Lyu2, Ruiqiang Zheng1,()   

  1. 1. Department of Critical Care Medicine, Subei People's Hospital of Jiangsu Province, Yangzhou 225000, China
    2. Department of General Surgery, Demei Rehabilitation Hospital, Xinghua 225700, China
  • Received:2018-03-11 Published:2018-05-28
  • Corresponding author: Ruiqiang Zheng
  • About author:
    Corresponding author: Zheng Ruiqiang, Email:
引用本文:

吕清泉, 顾小花, 陈齐红, 吕应鸣, 郑瑞强. 氢化可的松在肺部感染致感染性休克中应用的前瞻性临床研究[J/OL]. 中华重症医学电子杂志, 2018, 04(02): 141-146.

Qingquan Lyu, Xiaohua Gu, Qihong Chen, Yingming Lyu, Ruiqiang Zheng. Initiation of hydrocortisone treatment for pneumonia induced septic shock: a prospective clinical study[J/OL]. Chinese Journal of Critical Care & Intensive Care Medicine(Electronic Edition), 2018, 04(02): 141-146.

目的

探讨早期小剂量氢化可的松对肺部感染致感染性休克患者病死率的影响。

方法

采用前瞻性随机对照临床研究(RCT)方法,连续选择2015年9月至2017年2月收住于江苏省苏北人民医院重症监护病房(ICU)的54例肺部感染致感染性休克患者。将患者随机分为氢化可的松组和对照组。两组患者一旦使用血管活性药物,立即同时予以研究药物(氢化可的松或0.9%氯化钠溶液)持续静脉泵入。记录患者28 d病死率、住院病死率、休克逆转率、住ICU及住院时间等,评估早期小剂量氢化可的松的使用对肺部感染致感染性休克患者预后的影响。

结果

两组患者在28 d病死率、住院病死率、休克逆转率、住ICU时间及住院时间等方面差异均无统计学意义(均P>0.05)。二分类Logistic回归模型分析显示28 d内机械通气时间是肺部感染致感染性休克患者28 d病死率的独立影响因素(OR=0.654,95%CI:0.498~0.860,P=0.002)。而小剂量氢化可的松的应用在Logistic回归模型分析中差异无统计学意义(P>0.05)。

结论

在肺部感染致感染性休克患者中早期应用小剂量氢化可的松,并不能降低病死率、住ICU时间及住院时间。

Objective

To assess the effect of early initiation of low dose hydrocortisone on mortality in patients with pneumonia induced septic shock.

Methods

A prospective randomized controlled trial (RCT) was conducted in Department of Critical Care Medicine of Northern Jiangsu People′s Hospital. Fifty-four patients with pneumonia induced septic shock from September 2015 to February 2017 were enrolled in this study. Patients were randomly assigned to receive hydrocortisone or 0.9% sodium chloride solution at the same time of the vasopressors were initiated. In this study, 28-day mortality, hospital all-cause mortality, reversal of shock, length of stay in the ICU and hospital were recorded to evaluate the effect of early initiation of low-dose hydrocortisone treatment in patients with pneumonia induced septic shock.

Results

There were no significant differences in 28-day or hospital all-cause mortality; reversal of shock; length of stay in the ICU or hospital between patients treated with hydrocortisone and placebo (all P>0.05). The binary logistic regression model showed that duration of mechanical ventilation up to day 28 was an independent risk factor of 28-day mortality (P<0.05).

Conclusion

The early initiation of low-dose hydrocortisone did not decrease mortality, and the length of stay in the ICU or hospital in adults with pneumonia induced septic shock.

表1 氢化可的松组与对照组患者一般资料及入ICU病情比较
表2 氢化可的松组与对照组患者实验室检查及临床结果比较
项目 氢化可的松组(26例) 对照组(28例) 统计值 P
? 实验室检查 ? ? ? ?
? 白细胞[103/mm3,M(P25,P75)] 8.0(5.0,11.5) 10.5(4.9,16.1) H=1.386 0.239a
? 血小板[103/mm3,M(P25,P75)] 153.0(101.0,255.8) 168.5(132.5,275.0) H=1.026 0.311a
? 总胆红素[μmol/L,M(P25,P75)] 16.9(12.1,26.5) 16.1(10.0,21.8) H=0.594 0.441a
? 肌酐[μmol/L,M(P25,P75)] 144.5(81.5,198.8) 88.0(63.3,168.5) H=2.321 0.128a
? 凝血酶原时间(s,±s)) 17.7±5.4 16.9±5.2 t=0.537 0.594b
? 血清白蛋白(g/L,±s)) 27.6±5.7 29.4±5.9 t=-1.312 0.195b
? 乳酸(mmol/L,±s)) 5.5±4.2 4.4±3.5 t=1.094 0.279b
? 降钙素原[ng/ml,M(P25,P75)] 7.9(0.4,25.3) 1.35(0.2,9.4) H=2.321 0.128a
? 菌血症[例(%)] 5(19.2) 4(14.3) χ2=0.015 0.903d
痰培养阳性结果[例(%)] ? ? χ2=18.009 0.021c
? 肺炎链球菌 0(0.0) 2(7.1) - 0.491e
? 肺炎克雷伯氏菌 7(26.9) 5(17.9) χ2=0.641 0.423c
? 鲍曼不动杆菌 4(15.4) 12(42.9) χ2=4.880 0.027c
? 铜绿假单胞菌 0(0.0) 1(3.6) - 1.000e
? 嗜麦芽窄食单胞菌 2(7.7) 4(14.3) χ2=0.114 0.736d
? 大肠埃希菌 0(0.0) 3(10.7) χ2=1.261 0.261d
? 洋葱伯克霍尔德菌 0(0.0) 2(7.1) - 0.491e
? 耐甲氧西林金黄色葡萄球菌 3(11.5) 0(0.0) χ2=1.575 0.209d
? 其他 4(15.4) 15(53.6) χ2=8.620 0.003c
临床结果 ? ? ? ?
? 抗生素使用合理[例(%)] 18(69.2) 18(64.3) χ2=0.148 0.700c
? 升压药物使用前液体复苏量(L,±s 1.2±0.8 1.6±1.1 t=-1.760 0.084b
? 机械通气[例(%)] 26(100.0) 28(100.0) - -
? 肾脏替代治疗[例(%)] 10(38.5) 9(32.1) χ2=0.236 0.627c
表3 氢化可的松组与对照组患者病程结局比较
表4 28 d病死率的影响因素的Logistic回归模型分析
[1]
Brun-Buisson C,Meshaka P,Pinton P, et al. EPISEPSIS: a reappraisal of the epidemiology and outcome of se-vere sepsis in French intensive care units [J]. Intensive Care Med, 2004, 30(4): 580-588.
[2]
Kimmoun A,Ducrocq N,Levy B. Mechanisms of vascular hyporesponsiveness in septic shock [J]. Curr Vasc Pharmacol, 2013, 11(2): 139-149.
[3]
Huh JW,Choi HS,Lim CM, et al. Low-dose hydrocortisone treatment for patients with septic shock: a pilot study comparing 3 days with 7days [J]. Respirology, 2011, 16(7): 1088-1095.
[4]
Park HY,Suh GY,Song JU, et al. Early initiation of low-dose corticosteroid therapy in the management of septic shock: a retrospective observational study [J]. Crit Care, 2012, 16(1): R3.
[5]
Salluh JI,Verdeal JC,Mello GW, et al. Cortisol levels in patients with severe community-acquired pneumonia [J]. Intensive Care Med, 2006, 32(4): 595-598.
[6]
Yarema TC,Yost S. Low-dose corticosteroids to treat septic shock: a critical literature review [J]. Crit Care Nurse, 2011, 31(6): 16-26.
[7]
Wang C,Sun J,Zheng J, et al. Low-dose hydrocortisone therapy attenuates septic shock in adult patients but does not reduce 28-day mortality: a meta-analysis of randomized controlled trials [J]. Anesth Analg, 2014, 118(2): 346-357.
[8]
Creedon JM. Controversies surrounding critical illness-related corticosteroid insufficiency in animals [J]. J Vet Emerg Crit Care (San Antonio), 2015, 25(1): 107-112.
[9]
Lv Q,Gu X,Chen Q, et al. Early initiation of low-dose hydrocortisone treatment for septic shock in adults: a randomized clinical trial [J]. Am J Emerg Med, 2017, 35(12): 1810-1814.
[10]
Dellinger RP,Levy MM,Rhodes A, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012 [J]. Intensive Care Med, 2013, 39(2): 165-228.
[11]
Annane D,Sebille V,Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock [J]. JAMA, 2002, 288(7): 862-871.
[12]
Annane D,Renault A,Brun-Buisson C, et al. Hydrocortisone plus fludrocortisone for adults with septic shock [J]. N Engl J Med, 2018, 378(9): 809-818.
[13]
Venkatesh B,Finfer S,Cohen J, et al. Adjunctive glucocorticoid therapy in patients with septic shock [J]. N Engl J Med, 2018, 378(9): 797-808.
[14]
Arafah BM. Hypothalamic pituitary adrenal function during critical illness: limitations of current assessment methods [J]. J Clin Endocrinol Metab, 2006, 91(10): 3725-3745.
[15]
Patel GP,Balk RA. Systemic steroids in severe sepsis and septic shock [J]. Am J Respir Crit Care Med, 2012, 185(2): 133-139.
[16]
Sprung CL,Annane D,Keh D, et al. Hydrocortisone therapy for patients with septic shock [J]. N Engl J Med, 2008, 358(2): 111-124.
[17]
Tongyoo S,Permpikul C,Mongkolpun W, et al. Hydrocortisone treatment in early sepsis-associated acute respiratory distress syndrome: results of a randomized controlled trial [J]. Crit Care, 2016, 20(1): 329.
[18]
Czock D,Keller F,Rasche FM, et al. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids [J]. Clin Pharmacokinet, 2005, 44(1): 61-98.
[19]
Steigbigel NH. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock [J]. Curr Infect Dis Rep, 2003, 5(5): 363-364.
[20]
Jantz MA,Sahn SA. Corticosteroids in acute respiratory failure [J]. Am J Respir Crit Care Med, 1999, 160(4): 1079-1100.
[1] 农云洁, 黄小桂, 黄裕兰, 农恒荣. 超声在多重肺部感染诊断中的临床应用价值[J/OL]. 中华医学超声杂志(电子版), 2024, 21(09): 872-876.
[2] 曹楣汾, 李琼, 凌花, 陆勇, 戴新贵. RETRA评分在ICU收治创伤患者中的应用[J/OL]. 中华危重症医学杂志(电子版), 2024, 17(02): 130-135.
[3] 奚卫, 王闻卿, 刘玥, 王亚楠, 许学斌. 胃肠炎继发脓毒症感染创伤弧菌ST14514的病原学诊断与文献病例回顾分析[J/OL]. 中华实验和临床感染病杂志(电子版), 2024, 18(05): 293-302.
[4] 徐保平, 彭怀文, 喻怀斌, 王晓涛. 新型冠状病毒肺炎继发糖尿病酮症酸中毒合并肝门静脉积气一例[J/OL]. 中华实验和临床感染病杂志(电子版), 2024, 18(04): 250-255.
[5] 曾雪灵, 杨思园, 常宇飞, 赵红心, 王凌航. 176例人类免疫缺陷病毒合并肺部感染者呼吸道病原体特点与免疫学特征[J/OL]. 中华实验和临床感染病杂志(电子版), 2024, 18(03): 142-148.
[6] 董大红, 周明虎, 李芝朋, 许正峰. 碳青霉烯类抗生素联合呼吸机治疗肺部感染的临床疗效分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 793-796.
[7] 邢嘉翌, 龚佳晟, 祝佳佳, 陆群. 肺癌化疗患者继发肺部感染的病原菌耐药性及炎症因子变化分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 714-718.
[8] 郑玉, 许振浪, 陈青青. 类鼻疽致肺部感染患者的治疗及药学监护分析一例[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(04): 670-672.
[9] 罗懿, 王洪武. 宏基因组高通量测序在肺部感染中的应用[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(02): 320-323.
[10] 徐辉, 杨勇琼, 刘健, 许剑, 江佳莲, 邓正波. s-ChE、PCT、CRP在肺结核中的表达及继发肺部感染的预测意义[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(02): 292-295.
[11] 周润奭, 郑敏, 韩伟, 李尊柱, 何朝凯, 池熠, 隆云. 目标导向的集束化护理策略对多重耐药菌所致感染性休克患者28 d预后的影响[J/OL]. 中华重症医学电子杂志, 2024, 10(03): 236-242.
[12] 贾玲玲, 滕飞, 常键, 黄福, 刘剑萍. 心肺康复在各种疾病中应用的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 859-862.
[13] 李文哲, 王毅, 崔建, 郑启航, 王靖彦, 于湘友. 新疆维吾尔自治区重症患者急性肾功能异常的危险因素分析[J/OL]. 中华卫生应急电子杂志, 2024, 10(05): 269-276.
[14] 刘晴雯, 韩勇, 陈丽丹, 邓哲. 早期机械通气对成人院内心脏骤停病死率的影响:一项回顾性队列研究[J/OL]. 中华卫生应急电子杂志, 2024, 10(04): 203-206.
[15] 华美芳, 陈莉, 张峰林, 刘忠. 出血性脑卒中术后并发肺部感染的影响因素分析[J/OL]. 中华脑血管病杂志(电子版), 2024, 18(02): 110-114.
阅读次数
全文


摘要